NCT06297811 is a Phase 2 clinical trial of Trilaciclib Injection in Non-Small Cell Lung Cancer, sponsored by Sun Yat-sen University.

Who is sponsoring NCT06297811?

NCT06297811 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06297811?

Interventions in NCT06297811: Trilaciclib Injection, Paclitaxel, Carboplatin.

What condition does NCT06297811 study?

NCT06297811 studies Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer, Head And Neck Squamous Cell Carcinomas.

Is NCT06297811 still recruiting?

NCT06297811 is currently not yet recruiting. Last updated 7 March 2024.

Last reviewed 2024-03-07 · How we verify

NCT06297811

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myeloprotection With Trilaciclib in Pan-cancer Population

Not yet recruiting Phase 2 Last updated 7 March 2024

What this trial tests

Phase 2 trial testing Trilaciclib Injection in Non-Small Cell Lung Cancer in 132 participants. Not yet recruiting.

Timeline

1 March 2024

Primary endpoint
30 September 2025

31 December 2027

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	132
Start date	1 March 2024
Primary completion	30 September 2025
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

Trilaciclib Injection — full drug profile →
Paclitaxel — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Breast Cancer — all drugs for Breast Cancer →
Endometrial Cancer — all drugs for Endometrial Cancer →
Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population. The main questions it aims to answer are: * effect and safety of trilaciclib on myeloprotection in cancer patients receiving paclitaxel plus carboplatin chemotherapy * does trilaciclib 's myeloprotective efficacy in patients receiving the same chemotherapy regimen correlate with tumor type Participants will be randomized 2:1 to the treatment arm of trilaciclib in combination with a paclitaxel and carboplatin-based regimen and the control arm of a paclitaxel and carboplatin-based regimen for at least 6 cycles or until disease progression or intolerable toxicity. Patients in both groups could extend the chemotherapy cycle at the investigator 's discretion depending on the tumor type and in combination with anti-angiogenic/PD-X/anti-HER2 therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception.
Giarolla J, Holdaway KA, Nazari M, Aiad L, et al · · 2025 · cited 2× · PMID 40034037 · DOI 10.1080/17568919.2025.2463868
Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention.
Lei H, Fu J, Gu W, Qiao H, et al · · 2026 · PMID 41510186 · DOI 10.1002/mco2.70560

Verify or expand the search:

Other trials of Trilaciclib Injection

Trials testing the same drug.

NCT06328049 — A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC · Phase 2 · unknown

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06297811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 7 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06297811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing